INVESTORS & MEDIA
Bio Immunitas is led by an experienced team whose past achievements include
Awarded 2 USFDA Orphan Drug designations
Completed 2 separate UK MHRA registered Phase II double blind clinical trials successfully
years combined experience in biopharmaceuticals
>
0
selected publications by Professor Haq
years combined clinical experience
>
0
The longevity and anti-senescence market is expected to reach $44.2 billion by 2030*
* Opportunities and Forecast 2020-2030
Investor Opportunities
Bio Immunitas is an EIS-qualified Knowledge Intensive pharmaceutical company. All UK taxpayer investors, whether in the UK or overseas, can qualify for a minimum 30% tax rebate.
Funding already initiated for Phase 1 completion, with a view to Phase 2 clinical trial funding for specific indications, as defined in the pipeline.
Please get in touch for further information.
IP Position
in 2023
4 patents submitted in North America:
active patent filing program on-going with Fish & Richardson PC, Boston MA USA.